We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+2.85%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$14.8B
AUM Growth
+$2.92B
(+25%)
Cap. Flow
+$3.28B
Cap. Flow
% of AUM
22.14%
Top 10 Holdings %
Top 10 Hldgs %
12.56%
Holding
1,029
New
443
Increased
269
Reduced
185
Closed
112
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$217M |
| 2 |
Apple
AAPL
|
+$208M |
| 3 |
Microsoft
MSFT
|
+$199M |
| 4 |
Amazon
AMZN
|
+$136M |
| 5 |
Arthur J. Gallagher & Co
AJG
|
+$133M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ASML
ASML
|
+$125M |
| 2 |
Gilead Sciences
GILD
|
+$107M |
| 3 |
PR
Permian Resources
PR
|
+$85.4M |
| 4 |
Reddit
RDDT
|
+$84.1M |
| 5 |
Keysight
KEYS
|
+$79M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.96% |
| 2 | Technology | 25.64% |
| 3 | Financials | 7.58% |
| 4 | Industrials | 6.88% |
| 5 | Communication Services | 6.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
ImmunityBio
IBRX
$7.59B
| $8.81M | 0.06% |
3,442,440
+3,002,622
| +683% | +$12.5M |
|
|
PYCR
377
DELISTED
Paycor HCM, Inc. Common Stock
PYCR
| $8.8M | 0.06% |
473,690
+24,397
| +5% | +$407K |
|
378
Capricor Therapeutics
CAPR
$228M
| $8.69M | 0.06% |
+629,934
| New | +$11M |
|
|
UPB
379
Upstream Bio Inc
UPB
$367M
| $8.66M | 0.06% |
+526,511
| New | +$11.8M |
|
380
Enovis
ENOV
$1.74B
| $8.57M | 0.06% |
195,408
+76,408
| +64% | +$3.36M |
|
381
Ocular Therapeutix
OCUL
$1.87B
| $8.56M | 0.06% |
1,002,435
+2,435
| +0.2% | +$23.8K |
|
|
MASI
382
DELISTED
Masimo
MASI
| $8.46M | 0.06% |
51,185
+41,885
| +450% | +$6.61M |
|
383
Schneider National
SNDR
$6.4B
| $8.45M | 0.06% |
+288,681
| New | +$8.58M |
|
384
Synopsys
SNPS
$76.7B
| $8.45M | 0.06% |
+17,415
| New | +$9.1M |
|
|
GRDN
385
Guardian Pharmacy Services
GRDN
$2.56B
| $8.41M | 0.06% |
415,120
-153,011
| -27% | -$3.16M |
|
386
Lowe's Companies
LOW
$123B
| $8.41M | 0.06% |
+34,068
| New | +$9.1M |
|
|
FVR
387
FrontView REIT
FVR
$471M
| $8.28M | 0.06% |
+456,974
| New | +$8.64M |
|
388
Savara
SVRA
$1.13B
| $8.25M | 0.06% |
2,686,938
+381,743
| +17% | +$1.33M |
|
389
Spyre Therapeutics
SYRE
$9.06B
| $8.21M | 0.06% |
352,680
+88,424
| +33% | +$2.59M |
|
390
Rocket Pharmaceuticals
RCKT
$382M
| $8.2M | 0.06% |
652,421
+51,358
| +9% | +$773K |
|
391
TJX Companies
TJX
$177B
| $8.18M | 0.06% |
+67,734
| New | +$8.08M |
|
392
International Flavors & Fragrances
IFF
$22.5B
| $8.16M | 0.06% |
96,484
-37,960
| -28% | -$3.57M |
|
393
Phathom Pharmaceuticals
PHAT
$666M
| $8.13M | 0.06% |
1,001,692
-1,571,720
| -61% | -$19.5M |
|
394
Addus HomeCare
ADUS
$2.17B
| $8.04M | 0.05% |
64,176
-16,460
| -20% | -$2.08M |
|
395
Vornado Realty Trust
VNO
$7.51B
| $8.01M | 0.05% |
+190,512
| New | +$8.06M |
|
396
Citigroup
C
$231B
| $7.99M | 0.05% |
+113,578
| New | +$7.65M |
|
397
Olema Pharmaceuticals
OLMA
$1.01B
| $7.91M | 0.05% |
1,357,479
+3,293
| +0.2% | +$32.9K |
|
398
Allegion
ALLE
$14.3B
| $7.9M | 0.05% |
+60,423
| New | +$8.55M |
|
399
Lantheus
LNTH
$6.61B
| $7.87M | 0.05% |
88,018
+2,340
| +3% | +$228K |
|
400
Shake Shack
SHAK
$3B
| $7.84M | 0.05% |
60,378
+3,809
| +7% | +$467K |
|
Similar funds
PAM
TCIIS
UIM
VAI
Woodline Partners's Q4 2024 Portfolio in Review
As of Q4 2024, Woodline Partners held 1,029 positions worth $14.8B, up 25% from $11.9B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Woodline Partners deployed $3.28B of net new capital in Q4 2024, opening 443 new positions and adding to 269 existing holdings. Its largest new stake was TE Connectivity: 890,754 shares worth $127M.
By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 43% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Gilead Sciences, an estimated $107M trimmed.
- Woodline Partners's largest Q4 2024 buy was TE Connectivity: 890,754 shares worth $127M.
- Woodline Partners added most to NVIDIA in Q4 2024, an estimated $217M increase.
- Woodline Partners's biggest Q4 2024 reduction was Gilead Sciences, cutting an estimated $107M.
- Woodline Partners fully exited ASML in Q4 2024, selling an estimated $125M.
- Woodline Partners's ten largest holdings make up 13% of its $14.8B portfolio in Q4 2024.
- Woodline Partners opened 443 new positions and closed 112 in Q4 2024.
- Woodline Partners's portfolio value rose 25% quarter-over-quarter to $14.8B.
Based on Woodline Partners's 13F filing for Q4 2024, filed 14 Feb 2025.